Journal Information
Vol. 37. Issue 6.
Pages 467-468 (June 2018)
Share
Share
Download PDF
More article options
Vol. 37. Issue 6.
Pages 467-468 (June 2018)
Editorial comment
Open Access
Fabry disease: Something cardiologists must always bear in mind
Doença de Fabry – um lembrete obrigatório para os cardiologistas!
Visits
3820
Nuno Bettencourt
Unidade de Investigação Cardiovascular, Faculdade de Medicina da Universidade do Porto, Porto, Portugal
Related content
Rev Port Cardiol. 2018;37:457-6610.1016/j.repce.2018.03.015
Dulce Brito, Nuno Cardim, Luís Rocha Lopes, Adriana Belo, Jorge Mimoso, Lino Gonçalves, Hugo Madeira
This item has received

Under a Creative Commons license
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text

In this issue of the Journal, Brito et al. present a very interesting work1 based on data extracted from the Portuguese Registry of Hypertrophic Cardiomyopathy.2

Focusing on a non-mandatory question from this registry, concerning the exclusion of Anderson-Fabry disease in the differential diagnosis, the authors concluded that this entity is seldom studied in the workup of patients with unexplained left ventricular hypertrophy. According to their data, Fabry disease was recorded as excluded in only 27% of the patients included in the registry. Alpha-galactosidase A (α-Gal A) activity was assessed in 18% and GLA gene testing was only performed in 23% of cases. Among patients with potential red flags for Fabry disease (including concentric left ventricular hypertrophy, short or prolonged PR interval, intraventricular conduction disturbances or bradyarrhythmias requiring pacemaker implantation), fewer than half (47%) underwent specific tests (GLA gene testing and/or α-Gal A activity).

These results are even more striking if we note that only cardiology departments were included in the registry, which is totally voluntary, and that inclusion was not sequential. Bearing this in mind, there is a high probability of bias toward the inclusion of better-studied patients and a higher participation of centers with better overall performance in cardiomyopathies. This means that in real-world practice the rates of Fabry disease exclusion in these patients are probably even lower than reported here.

Portugal has some of the largest series of Fabry disease patients in Europe, and these numbers are mainly due to the systematic diagnostic workup performed in reference centers for lysosomal storage diseases.3–6 Although some geographic distribution patterns are clearly discernible, as can be expected from an X-linked genetic disease, it is essential to maintain general awareness of this disease, for which specific therapies are available that can modify prognosis. Since cardiac involvement is frequent and is sometimes the primary or sole manifestation of Fabry disease, all cardiologists should be constantly on the alert for the possibility of Fabry disease in the study of unexplained left ventricular hypertrophy. Early diagnosis and, if appropriate, initiation of enzyme replacement therapy can change the course of this disease and may improve both symptoms and prognosis. Furthermore, identification of an index case can help identify relatives affected by disease, who may also benefit from diagnostic workup, structured follow-up and early initiation of therapy, if indicated.

In an era of advanced imaging and readily available genetic testing, efforts should be made to ensure that red flags for Fabry disease in patients with left ventricular hypertrophy are identified and to encourage the use of dedicated tools for its exclusion. This paper has a clear message for all cardiologists: Fabry disease is something that must always be borne in mind in the study of patients with unexplained left ventricular hypertrophy.

Conflicts of interest

The author has no conflicts of interest to declare.

References
[1]
D. Brito, N. Cardim, L.R. Lopes, et al.
Awareness of Fabry disease in cardiology: a gap to be filled.
Rev Port Cardiol, 37 (2018), pp. 457-466
[2]
N. Cardim, D. Brito, L.R. Lopes, et al.
The Portuguese Registry of Hypertrophic Cardiomyopathy: overall results.
Rev Port Cardiol, 37 (2018), pp. 1-10
[3]
P. Aguiar, O. Azevedo, R. Pinto, et al.
Biomarkers of myocardial fibrosis: revealing the natural history of fibrogenesis in Fabry disease cardiomyopathy.
J Am Heart Assoc, 7 (2018, March),
[4]
J. Rodrigues, O. Azevedo, N. Sousa, et al.
Inner ear involvement in fabry disease: clinical and audiometric evaluation of a large cohort of patients followed in a reference centre.
Eur J Med Genet, (2018, January),
pii: S1769-7212(17)30574-8
[5]
D. Brito, G. Miltenberger-Miltenyi, O. Moldovan, et al.
Cardiac Anderson-Fabry disease: lessons from a 25-year-follow up.
Rev Port Cardiol, 33 (2014, April), pp. 247
e1–7
[6]
I. Beirão, A. Cabrita, M. Torres, et al.
Is it Fabry disease? Diagnostic and follow-up approach.
Acta Med Port, 29 (2016), pp. 85-87
Download PDF
Idiomas
Revista Portuguesa de Cardiologia (English edition)
Article options
Tools
en pt

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

By checking that you are a health professional, you are stating that you are aware and accept that the Portuguese Journal of Cardiology (RPC) is the Data Controller that processes the personal information of users of its website, with its registered office at Campo Grande, n.º 28, 13.º, 1700-093 Lisbon, telephone 217 970 685 and 217 817 630, fax 217 931 095, and email revista@spc.pt. I declare for all purposes that the information provided herein is accurate and correct.